Zeltia shares surge on positive late-stage cancer data

Shares of Spain's Zeltia shot up on the news that it has positive late-stage data for the ovarian cancer drug Yondelis to support its application for marketing approval. The developer plans to file in the U.S. and Europe in the last quarter of the year. Researchers for the company say that the data demonstrates that a combination of Yondelis and Doxil was significantly better than Doxil alone in halting tumor growth.

- read the report from The Guardian

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.